Alternative names

Technical specifications

• Antigen: CD105
• Clone: REAL218
• Isotype control: REAL Control
• Alternative names of antigen: ENG, END, HHT1, ORW1, Endoglin
• Distribution of antigen: endothelial cells, B cells, myeloid cells
• Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
• Storage: Store protected from light at 2–8 °C. Do not freeze.
• Available conjugates: FITC, PerCP

• Figure 1

  Human Umbilical Vein Endothelial Cells (HUVEC) were stained with REAlease CD105-FITC (B) or with the corresponding REAL Control (A). REAlease CD105-FITC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD105-FITC (D). Cells were and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

  A:	B:
  C:	D:

• Selected references

  1. Bellón, T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23(9): 2340-2345
  2. Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
  3. Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106